Form 483

Astellas Pharma Global Development, Inc. Form 483, 2012-02-27

FDA issued a Form 483 to Astellas Pharma Global Development, Inc. on 2012-02-27 with 2 public-safe observations.

483· Form 483 issued2 observations

Astellas Pharma Global Development, Inc. · Northbrook, United States · Issued February 27, 2012

Overview

  • 2 public-safe observations are available for this inspection.
  • 2 structured CFR citations are represented.
  • 2 investigators are tied to this Form 483.

Inspectional observations

Each observation cites the regulation FDA found the firm out of compliance with.

27 Feb 2012
21 CFR 312.50

Ensuring compliance with plan and protocol

Cited by Lequita M Mayhew, Bradley J Maunder

27 Feb 2012
21 CFR 812.43(c)(4)(i)

No investigation agreement statement of commitment

Cited by Lequita M Mayhew, Bradley J Maunder

Inspected site

APAstellas Pharma Global Development, Inc.Northbrook, United States

Inspection team

Cited regulations

CFR citations associated with this Form 483.

CitationWhat it coversCited
21 CFR 312.50Cited across public-safe Form 483 observations1x
21 CFR 812.43(c)(4)(i)Cited across public-safe Form 483 observations1x

Full 483 report

Get the verbatim text of all 2 observations

Every observation in full, so your team sees exactly what was cited and how it was answered.

  • The site's full inspection history around this Form 483
  • Whether these citations escalated to a warning letter
  • The investigators involved and the citations they repeat elsewhere